Image via PRN — Business Technology
Last updated
Amgen: Product Launch
European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial
Source: PRN — Business Technology
The leadership read
Amgen's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Amgen backs it with senior go-to-market hires across EMEA — that separates a platform move from a one-off.
Market context: MitchelLake's Talent Market Index sits at 104.6 (Hot), down 1.9 on the prior month; EMEA hiring signal is running easing (-2.2pts).
Amgen: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 58 days.
MitchelLake in this thematic
Also at Amgen →
More signals across Biotech & Pharma
Product Launch · EMEA
Boehringer Ingelheim →Boehringer Ingelheim initiated three Phase III clinical trials in precision oncology: two DAREON® programme trials (DAREON®-Lung-1 in SCLC and DAREON®-NEC-1 in epNEC) and Beamion LUNG-3 trial in HER2-mutant NSCLC. This represents advancement of biomarker-informed oncology pipeline.
Product Launch · EMEA
Bristol Myers Squibb →Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.
Partnership · EMEA
Flagship Pioneering →Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.
Ma Activity · EMEA
Biogen →Biogen completed acquisition of Apellis Pharmaceuticals, a leader in complement-driven disease treatments
Partnership · EMEA
UCB →UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Leadership Change · EMEA
BioMarin Pharmaceutical Inc. →Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier
Intelligence powered by Autonodal ↗